The development of multi-kinase inhibitors as pancreatic cancer therapeutics.

Abstract

Pancreatic cancer is an almost incurable malignancy whose incidence has increased over the past 30 years. Instead of pursuing the development of modalities utilizing 'traditional' cytotoxic chemotherapeutic agents, we have explored the possibilities of developing novel multi-kinase inhibitor drug combinations to kill this tumor type. Several approaches using the multi-kinase inhibitors sorafenib, regorafenib, and neratinib have been safely translated from the bench to the bedside, with objective anti-tumor responses. This review will discuss our prior preclinical and clinical studies and discuss future clinical opportunities in this disease.

• Authors: Paul Dent, Andrew Poklepovic, Laurence Booth, John F Hancock
• Journal: Anti-cancer drugs (Anticancer Drugs) Vol. 32 Issue 8 Pg. 779-785 (09 01 2021) ISSN: 1473-5741 [Electronic] England
• PMID: 34397447 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Review)
• Copyright: Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.

Chemical References

• Protein Kinase Inhibitors

Topics

• Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
• Clinical Trials as Topic
• Drug Resistance, Neoplasm
• Humans
• Pancreatic Neoplasms (pathology)
• Protein Kinase Inhibitors (pharmacology, therapeutic use)